Lever
Lifestyle
- Regular exercise
- Adequate hydration
- Blood pressure management
Blutwerte · Marker
eGFR
Estimated GFR · Glomeruläre Filtrationsrate · GFR · CKD-EPI
Nierenwerte
- Einheit:
- mL/min/1.73 m2
The eGFR test quantifies the estimated rate of blood filtration through the kidneys, based on serum creatinine levels.
Reference Ranges
Reference
60–120mL/min/1.73 m2
60
120
LowNormalHigh
Reference
Unit · mL/min/1.73 m2Values below 60 mL/min/1.73 m2 indicate potential kidney dysfunction. Age and sex can influence eGFR.
Overview
Übersicht
The estimated glomerular filtration rate (eGFR) is a blood biomarker used to assess kidney function by estimating the rate at which the kidneys filter waste from the blood. It is calculated using serum creatinine levels, age, sex, and sometimes race. Clinically, eGFR is crucial for diagnosing and staging chronic kidney disease (CKD), allowing for the monitoring of kidney function over time. Researchers have found that changes in eGFR can serve as surrogate endpoints in clinical trials for CKD progression. In the context of athletic performance and biohacking, maintaining optimal kidney function is essential for overall health and longevity, as the kidneys play a vital role in filtering metabolic waste and maintaining electrolyte balance. However, eGFR can be influenced by factors such as muscle mass, diet, and hydration status, which may affect its accuracy. Researchers observed that eGFR values can be confounded by acute changes in kidney function, and it is important to consider these factors when interpreting results.
Klinische Bedeutung
Elevated eGFR values may indicate hyperfiltration, often seen in early diabetic nephropathy. Reduced eGFR values suggest impaired kidney function, commonly associated with chronic kidney disease.
Dynamics
Trend Interpretation
Rising Values
Progressively rising eGFR values may indicate hyperfiltration or improved kidney function. Re-test in 3-6 months if changes are unexpected.
Falling Values
Progressively falling eGFR values suggest worsening kidney function. Further investigation and monitoring are recommended.
Re-test Interval
4 weeks if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- Increased muscle mass
- High protein diet
- Pregnancy
- Hyperfiltration states
Cause
Low Levels
- Chronic kidney disease
- Acute kidney injury
- Dehydration
- Heart failure
Protocol
How to Optimize
Lever
Nutrition
- Low sodium diet
- Adequate protein intake
- Avoidance of nephrotoxic substances
Note:
Consult with a healthcare provider before making significant dietary or lifestyle changes, especially if kidney disease is present.
Testing Guidelines
✓Fasting Not Required
✓Not Time-Sensitive
Testing Frequency
Annually for healthy adults, more frequently if at risk for kidney disease
Interfering Factors
- High protein intake
- Dehydration
- Recent intense exercise
Open Research Questions
Current research suggests that the optimal thresholds for eGFR as a surrogate endpoint in clinical trials for chronic kidney disease progression remain debated, particularly in early stages of the disease. Researchers have not yet established the full impact of confounders such as age and sex on the association between eGFR and Alzheimer's disease biomarkers. Additionally, clinical questions regarding the predictive value of eGFR in various populations and disease contexts remain unanswered.
22 Research Publications
8,535
Total Citations
9
Human/RCT
92.2
Avg. Influence
2026
Latest
Sort
Filter
01Top
#01
Revised equations for estimated GFR from serum creatinine in Japan.
HumanInfluence447.0
6093
This study examined new equations for estimating glomerular filtration rate (eGFR) in Japanese patients, finding that the new equations improved accuracy compared to previous models. Researchers validated these equations in a separate cohort, demonstrating better performance in estimating kidney function. The study highlights the importance of using population-specific coefficients for eGFR calculations.
02Top
#02
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
HumanInfluence67.0
1560
Researchers analyzed the overall survival outcomes of patients with advanced non-small-cell lung cancer based on their epidermal growth factor receptor (EGFR) mutation status. They found no significant difference in survival between treatments with gefitinib and carboplatin/paclitaxel overall, but noted that EGFR mutations were strong predictors of progression-free survival. The study highlighted the complexity of treatment responses based on biomarker status.
03Top
#03
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.
Meta-AnalysisInfluence29.0
476
Researchers found that changes in estimated glomerular filtration rate (eGFR) and albuminuria could serve as effective endpoints in clinical trials for chronic kidney disease (CKD). They observed that a reduction in eGFR slope was strongly associated with clinical outcomes. The study suggests that both eGFR and albuminuria changes can be used as surrogate markers for kidney disease progression under specific conditions.
04
#04
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
UnknownInfluence8.0
288
This study focused on the implementation of EGFR mutation testing in non-small cell lung cancer across Europe. Researchers found that standardized testing procedures are crucial for optimizing the use of EGFR tyrosine kinase inhibitors in clinical practice. The workshop emphasized the importance of timely testing and appropriate sampling techniques.
05
#05
Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications.
ReviewInfluence1.0
56
This review explored the structure and function of EGFR-targeted therapies in cancer treatment. Researchers highlighted the challenges of tumor resistance to these therapies and the importance of understanding molecular mechanisms for improving treatment efficacy. The study advocates for personalized approaches and combination therapies to overcome resistance.
06
#06
The impact of kidney function on Alzheimer's disease blood biomarkers: implications for predicting amyloid-β positivity.
HumanInfluence1.0
38
This study investigated the relationship between kidney function, measured by eGFR, and blood biomarkers for Alzheimer's disease (AD). Researchers observed that impaired kidney function was associated with higher levels of certain biomarkers, but these associations diminished when adjusting for age and sex. The findings suggest that eGFR has limited impact on the predictive value of AD biomarkers.
07
#07
Occupy EGFR.
Unknown
9
Researchers found that erlotinib and gefitinib, which inhibit EGFR, are less effective against glioblastoma-derived EGFR mutants. The study indicates that these drugs occupy the active sites of the mutants only minimally and suggests that other EGFR inhibitors may be more effective. This highlights the need for analyzing binding-site occupancy as a biomarker for treatment efficacy.
08
#08
Cytokine and epigenetic regulation of CEACAM6 mediates EGFR-driven signaling and drug response in lung adenocarcinoma.
Unknown
6
09
#09
The expression and clinical significance of STAMBP in breast cancer.
Li Lei, et al. · Molecular biology reports · 2023
Human
4
Researchers found that STAMBP expression is significantly higher in breast cancer tissues compared to noncancerous tissues. The study indicates that high STAMBP levels are associated with poor overall survival in breast cancer patients. Additionally, STAMBP knockdown reduced cancer cell mobility and invasion, suggesting its role as a potential biomarker for breast cancer progression.
Key findings
- 01STAMBP protein levels are significantly higher in breast cancer tumor cells compared to noncancerous tissues.
- 02Increased STAMBP expression is associated with larger tumors and more advanced cancer stages.
- 03Reducing STAMBP levels in cancer cells decreases their ability to move and invade other tissues.
10
#10
circ-EGFR is a predictor of response to Cetuximab and a potential target in colorectal cancer.
In Vitro
2
Clinical Trials (5)
5
Total Trials
583
Total Enrolled
Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
Sponsor
Beijing Biotech
Enrollment
60
Started
2026
Primary outcome
Incidence of dose-limiting toxicities (DLTs)
Non-Small Cell Lung CancerAdvanced/Metastatic
Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Enrollment
56
Started
2021
Primary outcome
Objective response rate (ORR)
Non-small Cell Lung Cancer Stage III
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
NCT02136862COMPLETED
Sponsor
Genzyme, a Sanofi Company
Enrollment
165
Started
2014
Primary outcome
To characterize the natural decline of renal function markers (Glomerular Filtration Rate [GFR] and creatinine) in patients with Alport syndrome over the course of up to 120 weeks
Alport Syndrome Patients With eGFR Between 45-90 ml/Min/1.73 m2
Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Sponsor
Gilead Sciences
Enrollment
252
Started
2013
Primary outcome
Change From Baseline in the Estimated Glomerular Filtration Rate Calculated by the Cockcroft-Gault Formula (eGFR_CG) at Week 24
HIVHIV Infections
Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant
NCT01759862COMPLETED
Sponsor
Stanford University
Enrollment
50
Started
2012
Primary outcome
Calculated Estimated Glomerular Filtration Rate (eGFR)
Function of Renal Transplant
Publication Trend
Research publications about eGFR over time
7totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer